# EDGAR Filing Document

**Accession Number:** 0001869105
**File Stem:** 0000950170-25-109842
**Filing Date:** 2025-8
**Character Count:** 7928
**Document Hash:** f6db3767daf79fca206455df41ac998f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-109842.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0000950170-25-109842

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250811

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001743881
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41955
- **FILM NUMBER:** 251228844

**BUSINESS ADDRESS:**
- **STREET 1:** 3160 PORTER DR.
- **STREET 2:** SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 391-9740

**MAIL ADDRESS:**
- **STREET 1:** 3160 PORTER DR.
- **STREET 2:** SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

**FORMER NAME:**
- **FORMER CONFORMED NAME:** BridgeBio Pharma LLC
- **DATE OF NAME CHANGE:** 20180618
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Pharma LLC
- **CENTRAL INDEX KEY:** 0002076615

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41955
- **FILM NUMBER:** 251228845

**BUSINESS ADDRESS:**
- **STREET 1:** C/O BRIDGEBIO PHARMA, INC.
- **STREET 2:** 3160 PORTER DRIVE, SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 391-9740

**MAIL ADDRESS:**
- **STREET 1:** C/O BRIDGEBIO PHARMA, INC.
- **STREET 2:** 3160 PORTER DRIVE, SUITE 250
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Oncology Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001869105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 857 702 0377

**MAIL ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp. II
- **DATE OF NAME CHANGE:** 20210623

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BridgeBio Pharma LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O BRIDGEBIO PHARMA, INC.<br>3160 PORTER DRIVE, SUITE 250<br><sub>(Street)</sub><br>PALO ALTO, CA 94304<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BridgeBio Oncology Therapeutics, Inc. [ BBOT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-08-11 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BridgeBio Pharma, Inc.<br><sub>(Last) (First) (Middle)</sub><br>3160 PORTER DR., SUITE 250<br><sub>(Street)</sub><br>PALO ALTO, CA 94304<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BridgeBio Oncology Therapeutics, Inc. [ BBOT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-08-11 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 13805126 | D<sup>(1)(2)</sup> |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2030-05-18 | Common Stock | 63934 | $3.83 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2030-05-18 | Common Stock | 9494 | $1.02 | D |  |

---

### Footnotes:

(1) Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collective, the BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.

(2) (Continued from Footnote 1) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

(3) The shares subject to such option are fully vested.

**Signature:** /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC  
**Date:** 2025-08-18

**Signature:** /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma, Inc.  
**Date:** 2025-08-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**